- LenioBio has partnered with ReciBioPharm, a CDMO, to scale up production of vaccine proteins using ALiCE technology.
- The collaboration supports the CEPI-funded 100 Days Mission aimed at expediting vaccine development.
LenioBio, a company specialising in cell-free protein expression technology, has entered a collaboration with ReciBioPharm, a contract development and manufacturing organisation (CDMO), to scale protein manufacturing and accelerate vaccine production. This partnership is part of an expansion of LenioBio’s CEPI-funded project, aligning with the 100 Days Mission, a global initiative to fast-track vaccine development timelines.
The collaboration follows LenioBio’s success in the initial phase of the project, where key milestones were met, including the small-scale production of vaccine proteins using the company’s proprietary ALiCE technology. In this next phase, ReciBioPharm will support the scaling of this production to a 10-litre capacity at their site in Oeiras, Portugal, enabling the generation of material for pre-clinical studies. This step is crucial in progressing towards GMP manufacturing for clinical trials.
André Goerke, CEO of LenioBio, expressed the importance of this collaboration, stating, “By transferring protein production with ALiCE to a leading CDMO, we aim to meet the urgent need for swift vaccine production, crucial for containing emerging health threats.”
ReciBioPharm brings expertise in biologics manufacturing, with the collaboration set to accelerate the use of ALiCE in scaled vaccine protein production. Vikas Gupta, President of ReciBioPharm, commented, “Our collaboration with LenioBio represents a significant step forward in recombinant protein manufacturing.”
As the project progresses, LenioBio plans to conduct further evaluations of protein quality through in vivo studies and continue regulatory discussions to position ALiCE as a rapid-deployment technology for vaccine and therapeutic development.
 Overview of outsourcing trends 
